Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO.
Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO – The BMJ Original Statement: Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 – World Health Organization Related recommendations: COVID-19: Joint statement from ECDC and EMA on the administration of a […]
The post Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO. appeared first on Links Medicus.
M-A: Antibiotic duration for community acquired pneumonia in outpatient children in high-income countries – treatment duration of 3–5 days is equally effective and safe vs. 7–10 days.
Antibiotic treatment duration for community acquired pneumonia in outpatient children in high-income countries – a systematic review and meta-analysis – Clinical Infectious Diseases Related: Antibiotics for Pediatric Pneumonia: Might Less Be Enough? – Annals of Emergency Medicine Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: […]
The post M-A: Antibiotic duration for community acquired pneumonia in outpatient children in high-income countries – treatment duration of 3–5 days is equally effective and safe vs. 7–10 days. appeared first on Links Medicus.
Systematic Review: Thoracic imaging tests for the diagnosis of COVID‐19.
Thoracic imaging tests for the diagnosis of COVID‐19 – Cochrane Library Summary: How accurate is chest imaging for diagnosing COVID-19? – Cochrane Library Related: Review of Thoracic Imaging Manifestations of COVID-19 and Other Pathologic Coronaviruses – Radiology Clinics of North America
The post Systematic Review: Thoracic imaging tests for the diagnosis of COVID‐19. appeared first on Links Medicus.
COVID-19 evidence: a Cochrane round-up.
COVID-19 evidence: a Cochrane round-up – Cochrane Library
The post COVID-19 evidence: a Cochrane round-up. appeared first on Links Medicus.
Review: Unexplained post-acute infection syndromes.
Unexplained post-acute infection syndromes – Nature Medicine (if the link is paywalled, try this one) Commentary on Twitter A @NatureMedicine tour de force review of the unexplained post-acute infectious syndromes, which includes #LongCovid and many others https://t.co/5RnyY9l0eQby @jan_choutka @mhornig @VirusesImmunity pic.twitter.com/dhYeZYnM1U — Eric Topol (@EricTopol) May 18, 2022
The post Review: Unexplained post-acute infection syndromes. appeared first on Links Medicus.
Opinion | Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data!
Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data! – STAT
The post Opinion | Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data! appeared first on Links Medicus.
The pandemic’s true health cost: how much of our lives has COVID stolen?
The pandemic’s true health cost: how much of our lives has COVID stolen? – Nature Commentary on Twitter What's missed by our fixation on hospitalization and death metrics for the pandemic—the disability toll—the impact by disability-adjusted life years (DALYs) https://t.co/dFWNuVah3z@HollyElse @Nature #LongCovid pic.twitter.com/Fql0a4ObLH — Eric Topol (@EricTopol) May 18, 2022
The post The pandemic’s true health cost: how much of our lives has COVID stolen? appeared first on Links Medicus.
Pollution and health: a progress update.
Pollution and health: a progress update – The Lancet Planetary Health Commentaries: One in six killed by pollution worldwide, study finds – CNN Pollution responsible for one in six deaths across planet, scientists warn – The Guardian Commentary on Twitter Pollution resulted in more than 9 million deaths and major losses in economic output […]
The post Pollution and health: a progress update. appeared first on Links Medicus.
Management of drug interactions with Nirmatrelvir/Ritonavir (Paxlovid).
Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians – Infectious Diseases Society of America Commentary: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist Related: Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic – STAT Yes, Relapses After Paxlovid Happen — Now What? […]
The post Management of drug interactions with Nirmatrelvir/Ritonavir (Paxlovid). appeared first on Links Medicus.
M-A: Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation.
Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation: a systematic review and meta-analysis – Critical Care
The post M-A: Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation. appeared first on Links Medicus.